Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Ashton

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, Against VEGFR-1 and Members of the Structurally Related PDGFR Family

Molecular Cancer Therapeutics
Cancer ResearchOncology
2011English

Combined Current and Temperature Mapping in an Air-Cooled, Open-Cathode Polymer Electrolyte Fuel Cell Under Steady-State and Dynamic Conditions

Journal of Power Sources
Electronic EngineeringSustainabilityEnergy EngineeringRenewable EnergyTheoretical ChemistryElectricalPower Technologythe EnvironmentPhysical
2015English

Related publications

Analysis of Biological Effects and Signaling Properties of FLT-1 (VEGFR-1) and KDR (VEGFR-2)

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2000English

A Case Report of Successful Treatment of Metastatic Gastral Neuroendocrine Carcinoma to a Small-Molecule VEGFR-2 Tyrosine Kinase Inhibitor Apatinib

Biomedical Research
2018English

Inhibitor of DNA Binding 1 (ID1); VEGF Receptor 2 (KDR/Flk-1; VEGFR-2)

Science-Business eXchange
2010English

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

Cancer Research
Cancer ResearchOncology
2008English

Generation and Characterization of a Human Nanobody Against VEGFR-2

Acta Pharmacologica Sinica
MedicinePharmacology
2016English

Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells

Cancers
Cancer ResearchOncology
2014English

Combined Blockade of VEGFR-2 and VEGFR-3 Inhibits Inflammatory Lymphangiogenesis in Early and Middle Stages

Investigative Ophthalmology and Visual Science
Molecular NeuroscienceOphthalmologySensory SystemsCellular
2011English

Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Rapamycin Suppresses Angiogenesis and Lymphangiogenesis in Melanoma by Downregulating VEGF-A/VEGFR-2 and VEGF-C/VEGFR-3 Expression

OncoTargets and Therapy
OncologyPharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy